Labstyle (DRIO) 1.4400 $DRIO
LabStyle Innovations Welcomes Professor Steven Kaplan to its Board of Directors
PR Newswire - Mon May 05, 7:55AM CDT
LabStyle Innovations Corp. (OTCQB: DRIO), developer of the Dario(TM) Diabetes Management Solution, announced today that world-renowned urologist and researcher, and co-founded numerous technology initiatives Professor Steven Kaplan, has joined the company's Board of Directors.
LabStyle Innovations Receives U.S. Notice of Allowance for Key Patent Relating to the Dario(TM) Blood Glucose Monitoring Device
PR Newswire - Thu May 01, 7:56AM CDT
LabStyle Innovations Corp. (OTCQB: DRIO), developer of the Dario(TM) Diabetes Management Solution, today announced that it has received a Notice of Allowance from the U.S. Patent and Trademark Office for core patent claims covering the company's personalized blood glucose monitoring device.
LabStyle Innovations Announces Reimbursement Coverage for the use of the Dario(TM) Personalized Smart Meter in Italy
PR Newswire - Mon Apr 28, 8:00AM CDT
LabStyle Innovations Corp. (OTCQB: DRIO), developer of the Dario(TM) Diabetes Management Solution, today announced that it has received national approval and regional reimbursement for the Dario(TM) Personalized Smart Meter in Italy.
SeeThruEquity Initiates Research Coverage on LabStyle Innovations with Target Price of $7.24
ACCESSWIRE - Thu Apr 24, 8:02AM CDT
New York, NY / ACCESSWIRE / April 24, 2014 / SeeThruEquity, a leading independent equity research and corporate access firm focused on smallcap and microcap public companies, today announced that it has initiated coverage on LabStyle Innovations Corp. (OTCQB: DRIO) with a target price of $7.24.
LabStyle Innovations Provides Recap of Investor Update Call
PR Newswire - Fri Apr 18, 9:17AM CDT
LabStyle Innovations Corp. (OTCQB: DRIO), developer of the Dario(TM) Diabetes Management Solution, provided a recap of the key messages delivered yesterday by the company's senior management Erez Raphael, president and chief executive officer, and Gadi Levin, chief financial officer, in an investor update call. A replay of the call can be accessed at http://mydario.investorroom.com/news-headlines
LabStyle Innovations to Hold Investor Update Conference Call On Thursday, April 17, 2014
PR Newswire - Thu Apr 10, 3:05PM CDT
LabStyle Innovations Corp. (OTCQB
RIO), developer of the Dario(TM) Diabetes Management Solution, announces that its president and chief executive officer, Mr. Erez Raphael, and its Chief Financial Officer, Mr. Gadi Levin, will host a conference call at 10 am Eastern Time on Thursday April 17, 2014 to report positive developments of the company's recent commercial launch of Dario in selected jurisdictions as well as an update on the company's commercial and regulatory plans for Dario for the remainder of 2014.
LabStyle Innovations Announces Partnership With Leading Global Nutrition Data Source For Its Dario Blood Glucose Monitoring Device
PR Newswire - Wed Apr 09, 6:15AM CDT
LabStyle Innovations Corp. (OTCQB: DRIO), developer of the Dario(TM) Diabetes Management Solution, today announced a partnership with the world's leading global nutrition data application, FatSecret.
Renowned Diabetes Authority Dr. William Polonsky Joins LabStyle Innovations Medical/Scientific Advisory Board
PR Newswire - Wed Apr 02, 6:15AM CDT
LabStyle Innovations Corp. (OTCQB RIO), developer of the Dario(TM) Diabetes Management Solution, today announced the appointment of Dr. William Polonsky to its Scientific/Medical Advisory Board.
IPOs and Transactions: March 17 - 21
PR Newswire - Mon Mar 24, 11:30AM CDT
There were 56 transactions filed with the SEC last week. Highlighted corporations and law firms include:
LabStyle Innovations Unveils Dario(TM) - The World's First Personalized Smart Meter
PR Newswire - Tue Mar 11, 11:53AM CDT
LabStyle Innovations Corp. (OTCQB: DRIO), developer of the Dario(TM) Diabetes Management Solution, today revealed the world's first personalized smart meter at the 26th Annual Roth Conference at the Ritz Carlton in Dana Point California.
LabStyle Innovations, Creator of Dario(TM) Diabetes mHealth Solution, to present at the 26th Annual Roth Conference on March 11, 2014
PR Newswire - Thu Mar 06, 3:01PM CST
LabStyle Innovations Corp. (OTCQB: DRIO), developer of the Dario(TM) Diabetes mHealth Solution, today announced that its president and chief executive officer, Mr. Erez Rafael, will be presenting at the 26th Annual Roth Conference. The presentation is scheduled for Tuesday, March 11, 2014 at 8:00 a.m. Pacific Time (11:00 a.m. Eastern Time) at the Ritz Carlton, Laguna Niguel, California.
LabStyle Innovations Announces 2013 Year End Results and Highlights Key Achievements and Anticipated 2014 Milestones
PR Newswire - Wed Mar 05, 6:15AM CST
LabStyle Innovations Corp. (OTCQB/OTCBB: DRIO), developer of the Dario(TM) Diabetes Management Solution, reported today its financial and operational results for the year ended December 31, 2013. The company also presented an overview of recent corporate achievements and anticipated milestones for 2014.
LabStyle Innovations Closes Private Placement Financing
PR Newswire - Thu Feb 20, 6:15AM CST
LabStyle Innovations Corp. (OTCQB: DRIO), developer of the Dario(TM) Diabetes Management Solution, announced today that it has successfully closed its previously announced $4.19 million common stock and warrant private placement financing that priced on February 13, 2014.
LabStyle Innovations Announces Pricing of $4.19 Million Private Placement Financing
PR Newswire - Thu Feb 13, 8:52AM CST
LabStyle Innovations Corp. (OTCQB RIO), developer of the Dario(TM) Diabetes Management Platform today announced that it has entered into a definitive securities purchase agreement with institutional and accredited investors to raise gross proceeds of $4.19 million at a price of $1.88 per unit in a private placement transaction. Each unit consists of one common share (for an aggregate of 2,226,956 shares to be sold) and three quarters (0.75) of one common share purchase warrant (for an aggregate of 1,670,216 warrants to be sold). The units will immediately detach and will not be separate securities. Each whole warrant entitles the holder to acquire one common share at a price of $2.35 for a period of five years from closing and contain certain anti-dilution provisions.
LabStyle Innovation Signs Agreement with uHealth to Exclusively Distribute the Dario(TM) Blood Glucose Monitoring Device in Australia
PR Newswire - Tue Feb 04, 6:00AM CST
LabStyle Innovations Corp. (OTCQB RIO), developer of the Dario(TM) Diabetes Management Platform, announced today that the company has signed an agreement with uHealth Australia Pty Limited (uHealth), a leading distributor of digital health and surgical innovations, to exclusively distribute in Australia the Dario(TM) blood glucose monitoring device, one of the three main components of the Dario(TM) platform.
LabStyle President and CEO Erez Raphael to Present and Demonstrate Dario(TM) at the Biotech Showcase 2014 in San Francisco, January 13, 2014 at 8:30 a.m.
Business Wire - Wed Jan 08, 5:59AM CST
LabStyle Innovations Corp. (OTCQB RIO), developer of Dario(TM), a cloud-based, mobile health platform for diabetes and blood glucose monitoring, announced today that company president and chief executive officer Mr. Erez Raphael will present at the Biotech Showcase 2014 on Monday, January 13, 2014 at 8:30 a.m., 55 Cyril Magnin Street, San Francisco, Level 4, Cyril Magnin Foyer. Mr. Raphael will address participants on the topic: "LabStyle Innovations Corp. (OTCQB RIO) End-to-End Smart Solutions for Diabetes in a Mobile Age." He will also give a hands-on demonstration of the Dario(TM) software and related blood glucose monitoring system and be available to answer questions.
LabStyle Innovations Files 510(k) in the U.S. for FDA Clearance of the Dario(TM) Blood Glucose Monitoring System
PR Newswire - Tue Jan 07, 6:00AM CST
LabStyle Innovations Corp. (OTCQB RIO), developer of Dario(TM), a cloud-based, mobile health platform for diabetes and blood glucose monitoring, announced today that it has filed a Premarket Notification Application, also known as a 510(k), with the US Food and Drug Administration (FDA) for the Dario(TM) Blood Glucose Monitoring System.
Diabetes Advocate and Opinion Leader David Edelman Joins LabStyle Innovations as Product Strategy Director
PR Newswire - Wed Dec 18, 6:00AM CST
LabStyle Innovations Corp. (OTCQB RIO), developer of Dario(TM), a cloud-based, mobile health platform for diabetes and blood glucose monitoring, announced that diabetes advocate and opinion leader David Edelman has joined the company as the new director of product strategy. He is also the newest member of the company's scientific advisory board (SAB).
LabStyle Innovations Commences World Roll-Out of the Dario(TM) Diabetes Management Platform with Market Launch of iOS App in the United Kingdom, New Zealand and Australia
PR Newswire - Thu Dec 12, 6:00AM CST
LabStyle Innovations Corp. (OTCQB: DRIO), developer of Dario(TM), a cloud-based, mobile health (mHealth) platform for diabetes and related blood glucose monitoring, announced that the world roll-out of the Dario(TM) diabetes management platform is now in progress with today's market launch of the Dario(TM) iOS app in the United Kingdom, New Zealand and Australia.
LabStyle Innovations Appoints Mr. Gadi Levin as Chief Financial Officer
PR Newswire - Wed Nov 27, 11:00AM CST
LabStyle Innovations Corp. (OTCQB RIO), developer of Dario(TM), a cloud-based, mobile health (mHealth) platform for diabetes management and related blood glucose monitoring, announced that Mr. Gadi Levin, CPA, MBA, has been appointed as the company's chief financial officer, secretary and treasurer.
LabStyle Innovations Welcomes Professor Steven Kaplan to its Board of Directors
PR Newswire - Mon May 05, 7:55AM CDT
LabStyle Innovations Corp. (OTCQB: DRIO), developer of the Dario(TM) Diabetes Management Solution, announced today that world-renowned urologist and researcher, and co-founded numerous technology initiatives Professor Steven Kaplan, has joined the company's Board of Directors.
LabStyle Innovations Receives U.S. Notice of Allowance for Key Patent Relating to the Dario(TM) Blood Glucose Monitoring Device
PR Newswire - Thu May 01, 7:56AM CDT
LabStyle Innovations Corp. (OTCQB: DRIO), developer of the Dario(TM) Diabetes Management Solution, today announced that it has received a Notice of Allowance from the U.S. Patent and Trademark Office for core patent claims covering the company's personalized blood glucose monitoring device.
LabStyle Innovations Announces Reimbursement Coverage for the use of the Dario(TM) Personalized Smart Meter in Italy
PR Newswire - Mon Apr 28, 8:00AM CDT
LabStyle Innovations Corp. (OTCQB: DRIO), developer of the Dario(TM) Diabetes Management Solution, today announced that it has received national approval and regional reimbursement for the Dario(TM) Personalized Smart Meter in Italy.
SeeThruEquity Initiates Research Coverage on LabStyle Innovations with Target Price of $7.24
ACCESSWIRE - Thu Apr 24, 8:02AM CDT
New York, NY / ACCESSWIRE / April 24, 2014 / SeeThruEquity, a leading independent equity research and corporate access firm focused on smallcap and microcap public companies, today announced that it has initiated coverage on LabStyle Innovations Corp. (OTCQB: DRIO) with a target price of $7.24.
LabStyle Innovations Provides Recap of Investor Update Call
PR Newswire - Fri Apr 18, 9:17AM CDT
LabStyle Innovations Corp. (OTCQB: DRIO), developer of the Dario(TM) Diabetes Management Solution, provided a recap of the key messages delivered yesterday by the company's senior management Erez Raphael, president and chief executive officer, and Gadi Levin, chief financial officer, in an investor update call. A replay of the call can be accessed at http://mydario.investorroom.com/news-headlines
LabStyle Innovations to Hold Investor Update Conference Call On Thursday, April 17, 2014
PR Newswire - Thu Apr 10, 3:05PM CDT
LabStyle Innovations Corp. (OTCQB
RIO), developer of the Dario(TM) Diabetes Management Solution, announces that its president and chief executive officer, Mr. Erez Raphael, and its Chief Financial Officer, Mr. Gadi Levin, will host a conference call at 10 am Eastern Time on Thursday April 17, 2014 to report positive developments of the company's recent commercial launch of Dario in selected jurisdictions as well as an update on the company's commercial and regulatory plans for Dario for the remainder of 2014. LabStyle Innovations Announces Partnership With Leading Global Nutrition Data Source For Its Dario Blood Glucose Monitoring Device
PR Newswire - Wed Apr 09, 6:15AM CDT
LabStyle Innovations Corp. (OTCQB: DRIO), developer of the Dario(TM) Diabetes Management Solution, today announced a partnership with the world's leading global nutrition data application, FatSecret.
Renowned Diabetes Authority Dr. William Polonsky Joins LabStyle Innovations Medical/Scientific Advisory Board
PR Newswire - Wed Apr 02, 6:15AM CDT
LabStyle Innovations Corp. (OTCQB
RIO), developer of the Dario(TM) Diabetes Management Solution, today announced the appointment of Dr. William Polonsky to its Scientific/Medical Advisory Board. IPOs and Transactions: March 17 - 21
PR Newswire - Mon Mar 24, 11:30AM CDT
There were 56 transactions filed with the SEC last week. Highlighted corporations and law firms include:
LabStyle Innovations Unveils Dario(TM) - The World's First Personalized Smart Meter
PR Newswire - Tue Mar 11, 11:53AM CDT
LabStyle Innovations Corp. (OTCQB: DRIO), developer of the Dario(TM) Diabetes Management Solution, today revealed the world's first personalized smart meter at the 26th Annual Roth Conference at the Ritz Carlton in Dana Point California.
LabStyle Innovations, Creator of Dario(TM) Diabetes mHealth Solution, to present at the 26th Annual Roth Conference on March 11, 2014
PR Newswire - Thu Mar 06, 3:01PM CST
LabStyle Innovations Corp. (OTCQB: DRIO), developer of the Dario(TM) Diabetes mHealth Solution, today announced that its president and chief executive officer, Mr. Erez Rafael, will be presenting at the 26th Annual Roth Conference. The presentation is scheduled for Tuesday, March 11, 2014 at 8:00 a.m. Pacific Time (11:00 a.m. Eastern Time) at the Ritz Carlton, Laguna Niguel, California.
LabStyle Innovations Announces 2013 Year End Results and Highlights Key Achievements and Anticipated 2014 Milestones
PR Newswire - Wed Mar 05, 6:15AM CST
LabStyle Innovations Corp. (OTCQB/OTCBB: DRIO), developer of the Dario(TM) Diabetes Management Solution, reported today its financial and operational results for the year ended December 31, 2013. The company also presented an overview of recent corporate achievements and anticipated milestones for 2014.
LabStyle Innovations Closes Private Placement Financing
PR Newswire - Thu Feb 20, 6:15AM CST
LabStyle Innovations Corp. (OTCQB: DRIO), developer of the Dario(TM) Diabetes Management Solution, announced today that it has successfully closed its previously announced $4.19 million common stock and warrant private placement financing that priced on February 13, 2014.
LabStyle Innovations Announces Pricing of $4.19 Million Private Placement Financing
PR Newswire - Thu Feb 13, 8:52AM CST
LabStyle Innovations Corp. (OTCQB
RIO), developer of the Dario(TM) Diabetes Management Platform today announced that it has entered into a definitive securities purchase agreement with institutional and accredited investors to raise gross proceeds of $4.19 million at a price of $1.88 per unit in a private placement transaction. Each unit consists of one common share (for an aggregate of 2,226,956 shares to be sold) and three quarters (0.75) of one common share purchase warrant (for an aggregate of 1,670,216 warrants to be sold). The units will immediately detach and will not be separate securities. Each whole warrant entitles the holder to acquire one common share at a price of $2.35 for a period of five years from closing and contain certain anti-dilution provisions. LabStyle Innovation Signs Agreement with uHealth to Exclusively Distribute the Dario(TM) Blood Glucose Monitoring Device in Australia
PR Newswire - Tue Feb 04, 6:00AM CST
LabStyle Innovations Corp. (OTCQB
RIO), developer of the Dario(TM) Diabetes Management Platform, announced today that the company has signed an agreement with uHealth Australia Pty Limited (uHealth), a leading distributor of digital health and surgical innovations, to exclusively distribute in Australia the Dario(TM) blood glucose monitoring device, one of the three main components of the Dario(TM) platform. LabStyle President and CEO Erez Raphael to Present and Demonstrate Dario(TM) at the Biotech Showcase 2014 in San Francisco, January 13, 2014 at 8:30 a.m.
Business Wire - Wed Jan 08, 5:59AM CST
LabStyle Innovations Corp. (OTCQB
RIO), developer of Dario(TM), a cloud-based, mobile health platform for diabetes and blood glucose monitoring, announced today that company president and chief executive officer Mr. Erez Raphael will present at the Biotech Showcase 2014 on Monday, January 13, 2014 at 8:30 a.m., 55 Cyril Magnin Street, San Francisco, Level 4, Cyril Magnin Foyer. Mr. Raphael will address participants on the topic: "LabStyle Innovations Corp. (OTCQB RIO) End-to-End Smart Solutions for Diabetes in a Mobile Age." He will also give a hands-on demonstration of the Dario(TM) software and related blood glucose monitoring system and be available to answer questions. LabStyle Innovations Files 510(k) in the U.S. for FDA Clearance of the Dario(TM) Blood Glucose Monitoring System
PR Newswire - Tue Jan 07, 6:00AM CST
LabStyle Innovations Corp. (OTCQB
RIO), developer of Dario(TM), a cloud-based, mobile health platform for diabetes and blood glucose monitoring, announced today that it has filed a Premarket Notification Application, also known as a 510(k), with the US Food and Drug Administration (FDA) for the Dario(TM) Blood Glucose Monitoring System. Diabetes Advocate and Opinion Leader David Edelman Joins LabStyle Innovations as Product Strategy Director
PR Newswire - Wed Dec 18, 6:00AM CST
LabStyle Innovations Corp. (OTCQB
RIO), developer of Dario(TM), a cloud-based, mobile health platform for diabetes and blood glucose monitoring, announced that diabetes advocate and opinion leader David Edelman has joined the company as the new director of product strategy. He is also the newest member of the company's scientific advisory board (SAB). LabStyle Innovations Commences World Roll-Out of the Dario(TM) Diabetes Management Platform with Market Launch of iOS App in the United Kingdom, New Zealand and Australia
PR Newswire - Thu Dec 12, 6:00AM CST
LabStyle Innovations Corp. (OTCQB: DRIO), developer of Dario(TM), a cloud-based, mobile health (mHealth) platform for diabetes and related blood glucose monitoring, announced that the world roll-out of the Dario(TM) diabetes management platform is now in progress with today's market launch of the Dario(TM) iOS app in the United Kingdom, New Zealand and Australia.
LabStyle Innovations Appoints Mr. Gadi Levin as Chief Financial Officer
PR Newswire - Wed Nov 27, 11:00AM CST
LabStyle Innovations Corp. (OTCQB
RIO), developer of Dario(TM), a cloud-based, mobile health (mHealth) platform for diabetes management and related blood glucose monitoring, announced that Mr. Gadi Levin, CPA, MBA, has been appointed as the company's chief financial officer, secretary and treasurer. 
